Development of an ELISA for the detection of 2-nitroimidazole hypoxia markers bound to tumor tissue.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 1310494.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Canine and rodent tumors covalently bind the fluorinated 2-nitroimidazole, CCI-103F, in a way that immunohistochemical analysis shows is consistent with the location of tumor hypoxia. We have now developed a rapid, quantitative, and non-radioactive enzyme linked immunosorbent assay for the binding of CCI-103F in biopsy samples of spontaneous canine tumors. Issues of antigen stability during tissue processing, calibration of the ELISA, and the use of biopsy samples for measuring tumor hypoxia by the ELISA approach are addressed.
Medical subject headings
- Cell Hypoxia
- Enzyme-Linked Immunosorbent Assay
- Neoplasms
- Nitroimidazoles